← Human Trials & Peer-Reviewed Studies
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial
Plain-language guide to PMID 19933912 (2010): open-label clinical trial, phase ii study of Octreotide in 78 patients, pancreatitis (after the acute phase).
Key Facts
- PMID
- 19933912
- Journal
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- Year
- 2010
- Study type
- Clinical Trial, Phase II
- Authors
- Yao JC et al. (19 authors)
- DOI
- 10.1200/JCO.2009.24.2669
What This Study Did, in Plain Language
What Was Tested
Researchers studied Octreotide in the context of pancreatitis (after the acute phase) in this clinical trial, phase ii publication.
PURPOSE No established treatment exists for pancreatic neuroendocrine tumor (NET) progression after failure of chemotherapy.
Why It Was Studied
PATIENTS AND METHODS This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy.
Tumor assessments (using Response Evaluation Criteria in Solid Tumors) were performed every 3 months.
Who Took Part
The study group was 78 patients.
The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.
How the Study Was Run
The design is described as open-label.
Being open-label, the Octreotide study did not mask who received what.
Chromogranin A (CgA) and neuron-specific enolase (NSE) were assessed monthly if elevated at baseline.
Trough concentrations of everolimus and octreotide were assessed.
What Was Measured
PATIENTS AND METHODS This open-label, phase II study assessed the clinical activity of everolimus in patients with metastatic pancreatic NETs who experienced progression on or after chemotherapy.
Tumor assessments (using Response Evaluation Criteria in Solid Tumors) were performed every 3 months.
The subject headings attached to it are Antineoplastic Combined Chemotherapy Protocols, Chromogranin A, Disease-Free Survival, Everolimus, Neuroendocrine Tumors, Octreotide and Pancreatic Neoplasms.
What This Means in Plain Language
The paper is an open-label study of Octreotide in 78 patients in people with pancreatitis (after the acute phase).
The publication is from 2010 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.
More context: the Octreotide compound page, Pancreatitis (after the acute phase) research.
Our Notes on the Compound
Octreotide: An 8-amino-acid somatostatin analog (Sandostatin, Mycapssa) used for acromegaly and certain hormone-secreting tumors.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.